Cixutumumab and octreotide combination evaluated for 6-month progression-free survival in metastatic neuroendocrine tumors
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Abstract
A phase II study aims to determine the 6-month progression-free survival rate of cixutumumab combined with depot octreotide acetate in metastatic neuroendocrine tumor patients.